Obesity, Surgery, and Optimizing Patient Care Rheumatologic care requires a multidisciplinary approach and collaboration with other specialties to treat complex systemic diseases. While many Pods at RheumNow Live are disease-specific, the Pod II focused on Advancing Practice on https://t.co/hvSY5yHZmd

The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field. https://t.co/KuVei8jiFu https://t.co/PR4h2qniEL

RT @RichardPAConway Comparative survival in incident RA-ILD 1955-1995 vs 1999-2014. We are getting better, althoug need to take into account the general survival improvement also. More work to do! #RNL26 https://t.co/VwV33tHgR8

RT @ericdeinMD #RNL26 @RheumNow Uzma Haque GLP1 on pts with  SLE and diabetes Retrospective study - major improvements in MACE HR 0.66 VTE HR 0.49 Renal progession HR 0.77 Mortality HR 0.26 A major tool for rheumatic care! https://t.co/qR3HKfsugZ

RT @gibson_rheumPAC Gout flares are not benign. Recent flares double MI/stroke risk and markedly increase CV mortality—making flare prevention vital.#RNL26 https://t.co/gKvqo3vFYb

RT @gibson_rheumPAC Baseline serum urate >8–9 mg/dL strongly predicts worse flares, hospitalizations, and joint damage over years. Urate level should inform urgency and intensity of therapy. #RNL26 https://t.co/4RBVXZxCCX

RT @gibson_RheumPAC Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4

RT @Gibson_RheumPAC A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo

RT @ericdeinMD #RNL26 GLP on Knee OA STEP 9 Trial - 68 wk Mean WOMAC improved by 41.7 pts, compared to 27.5 in PBO, improved SF-36 7% stopped due to side effects https://t.co/LJzGzzlgq6 https://t.co/5ybyUdfNjZ